Conversion Therapy with Irinotecan Liposome (II) plus Oxaliplatin, 5-FU/S-1, Adebrelimab, and Recaticimab in Borderline Resectable or Locally Advanced Pancreatic Cancer: A Single-Arm Exploratory Study

Authors
Category Primary study
Registry of TrialsChinese Clinical Trial Register
Year 2026
This article has no abstract
Epistemonikos ID: 52c720cd7bba44405b138cc2dea493bf2366e8a9
First added on: Oct 10, 2026